文献检索/Drug SafetyEM-T3Drug Safety2021-02-02第 44 卷第 5 期，515-530开放获取高影响力 · 前 10%Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III ProgramPhilip G. ConaghanUniversity of LeedsEduardo MyslerYoshiya TanakaUniversity of Occupational and Environmental Health JapanBarbara A. Da Silva-TillmannAbbVie (United States)Tim ShawAbbVie (United Kingdom)John LiuAbbVie (United States)Ryan FergusonAbbVie (United States)Jeffrey EnejosaAbbVie (United States)Stanley B. CohenMetroplex Clinical Research CenterPeter T. NashGriffith UniversityWilliam F. C. RigbyDartmouth–Hitchcock Medical CenterGerd Rüdiger BurmesterCharité – Universitätsmedizin Berlin开放获取全文去出版社页面 引用论文图谱收藏 被引提醒分享打印登录后看摘要和中文要点英文摘要、AI 生成的中文摘要和三条要点、参考文献和引证文献列表、论文图谱，注册免费。登录 / 注册关键词upadacitinibrheumatoid arthritisJAK inhibitorsrisk-benefit assessmenttreat-to-targetclinical remissionlow disease activityherpes zostercreatine kinase elevationserious infectionscardiovascular eventsvenous thromboembolismmethotrexateadalimumab参考文献73引证文献2相似文献引文网络关联作者相关机构登录后可以看完整列表。去登录论文图谱本篇和它的参考文献、引证文献、相似文献登录后可以看这篇的论文图谱：谁被它引用、谁引用了它、还有哪些相似的研究。登录 / 注册
